Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA
- New headquarters includes 80,000 square feet of office, laboratory, and manufacturing space to advance the development of Adverum’s novel gene therapies -
“We are excited to open our corporate headquarters and for our team to become part of Redwood City’s vibrant biotechnology and business community,” said
This state-of the-art facility includes two buildings, located at
Statements contained in this press release regarding events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements regarding: Adverum’s plans to advance ADVM-022, including pursuing an indication in diabetic retinopathy, to grow its workforce, and to expand its process development and manufacturing capabilities, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not achieve any of these in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the results of early clinical trials not always being predictive of future results; the potential for future complications or side effects in connection with use of ADVM-022; obtaining regulatory approval for gene therapy product candidates; enrolling patients in clinical trials; reliance on third parties for conducting clinical trials and vector production; and ability to fund operations. Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q filed with the
Investor and Media Inquiries: Investors:
Myesha Lacy Adverum Biotechnologies, Inc.email@example.com 1-650-649-1257 Media: Cherilyn Cecchini, M.D. LifeSci Communicationsccecchini@lifescicomms.com 1-646-876-5196
Source: Adverum Biotechnologies, Inc.